PureTech Health plc Performance
| PTCHFDelisted Stock | USD 3.13 0.00 0.00% |
The company holds a Beta of 0.0393, which implies not very significant fluctuations relative to the market. As returns on the market increase, PureTech Health's returns are expected to increase less than the market. However, during the bear market, the loss of holding PureTech Health is expected to be smaller as well. PureTech Health plc right now holds a risk of 0.0%. Please check PureTech Health plc downside variance, and the relationship between the maximum drawdown and skewness , to decide if PureTech Health plc will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PureTech Health plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical indicators, PureTech Health is not utilizing all of its potentials. The newest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 403.9 M | |
| Total Cashflows From Investing Activities | 197.4 M |
PureTech |
PureTech Health Relative Risk vs. Return Landscape
If you would invest 313.00 in PureTech Health plc on September 3, 2024 and sell it today you would earn a total of 0.00 from holding PureTech Health plc or generate 0.0% return on investment over 90 days. PureTech Health plc is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than PureTech, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
PureTech Health Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PureTech Health's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as PureTech Health plc, and traders can use it to determine the average amount a PureTech Health's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PTCHF |
Based on monthly moving average PureTech Health is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PureTech Health by adding PureTech Health to a well-diversified portfolio.
PureTech Health Fundamentals Growth
PureTech Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of PureTech Health, and PureTech Health fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PureTech Pink Sheet performance.
| Return On Equity | -0.0152 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.73) % | ||||
| Operating Margin | (9.87) % | ||||
| Current Valuation | 654.5 M | ||||
| Shares Outstanding | 278.81 M | ||||
| Price To Earning | 158.00 X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 51.23 X | ||||
| Revenue | 9.98 M | ||||
| EBITDA | (46.95 M) | ||||
| Cash And Equivalents | 368.03 M | ||||
| Cash Per Share | 1.28 X | ||||
| Total Debt | 14.26 M | ||||
| Debt To Equity | 0.08 % | ||||
| Book Value Per Share | 2.03 X | ||||
| Cash Flow From Operations | (158.27 M) | ||||
| Earnings Per Share | (0.21) X | ||||
| Total Asset | 946.01 M | ||||
About PureTech Health Performance
By analyzing PureTech Health's fundamental ratios, stakeholders can gain valuable insights into PureTech Health's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PureTech Health has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PureTech Health has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. PURETECH HEALTH operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 95 people.Things to note about PureTech Health plc performance evaluation
Checking the ongoing alerts about PureTech Health for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for PureTech Health plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PureTech Health plc is not yet fully synchronised with the market data | |
| PureTech Health plc has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 9.98 M. Net Loss for the year was (60.56 M) with profit before overhead, payroll, taxes, and interest of 17.39 M. | |
| PureTech Health plc has accumulated about 368.03 M in cash with (158.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. | |
| Roughly 72.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology Annual Meeting in 16 RelapsedRefractory AL Amyloidosis Patients |
- Analyzing PureTech Health's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PureTech Health's stock is overvalued or undervalued compared to its peers.
- Examining PureTech Health's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PureTech Health's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PureTech Health's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PureTech Health's pink sheet. These opinions can provide insight into PureTech Health's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in PureTech Pink Sheet
If you are still planning to invest in PureTech Health plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PureTech Health's history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |